Inogen Inc. (NASDAQ:INGN) EVP Matt Scribner sold 4,551 shares of the firm’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $60.18, for a total transaction of $273,879.18. Following the completion of the transaction, the executive vice president now directly owns 6,884 shares of the company’s stock, valued at approximately $414,279.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Matt Scribner also recently made the following trade(s):
- On Thursday, August 18th, Matt Scribner sold 2,320 shares of Inogen stock. The shares were sold at an average price of $56.39, for a total transaction of $130,824.80.
- On Monday, July 18th, Matt Scribner sold 4,102 shares of Inogen stock. The shares were sold at an average price of $50.46, for a total transaction of $206,986.92.
Inogen Inc. (NASDAQ:INGN) opened at 61.04 on Monday. The company has a market cap of $1.23 billion, a P/E ratio of 89.76 and a beta of 0.88. Inogen Inc. has a 12 month low of $28.81 and a 12 month high of $61.87. The stock has a 50 day moving average of $58.03 and a 200-day moving average of $49.92.
Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Thursday, August 4th. The medical technology company reported $0.25 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.05. Inogen had a net margin of 7.86% and a return on equity of 9.50%. The company had revenue of $54.57 million for the quarter, compared to analyst estimates of $52.44 million. During the same period in the prior year, the firm posted $0.17 EPS. The company’s quarterly revenue was up 23.9% on a year-over-year basis. Equities research analysts expect that Inogen Inc. will post $0.63 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. bought a new position in Inogen during the second quarter worth about $1,856,000. Mason Street Advisors LLC bought a new position in Inogen during the second quarter worth about $142,000. Royal Bank of Canada increased its position in Inogen by 946.1% in the second quarter. Royal Bank of Canada now owns 257,941 shares of the medical technology company’s stock worth $12,926,000 after buying an additional 233,283 shares during the last quarter. IFP Advisors Inc increased its position in Inogen by 0.3% in the second quarter. IFP Advisors Inc now owns 2,086 shares of the medical technology company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Finally, Arizona State Retirement System increased its position in Inogen by 2.7% in the second quarter. Arizona State Retirement System now owns 7,500 shares of the medical technology company’s stock worth $376,000 after buying an additional 200 shares during the last quarter.
A number of research firms recently weighed in on INGN. Zacks Investment Research downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. JPMorgan Chase & Co. lifted their price objective on shares of Inogen from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Friday, August 5th. Needham & Company LLC reissued a “strong-buy” rating and issued a $64.00 price objective (up previously from $58.00) on shares of Inogen in a research report on Sunday, August 7th. Stifel Nicolaus downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. They noted that the move was a valuation call. Finally, Leerink Swann reissued an “outperform” rating and issued a $60.00 price objective on shares of Inogen in a research report on Wednesday, June 8th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Inogen has an average rating of “Buy” and a consensus price target of $55.00.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Receive News & Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.